Initial MAGE-A4 T-cell collaboration program
set to enter clinic ahead of schedule by end of 2023
Companies plan to add programs in oncology and
autoimmune disease to collaboration
2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology
cell therapy company, and JW Therapeutics (HKEX: 2126), an
independent and innovative biotechnology company focusing on
developing, manufacturing and commercializing cell immunotherapy
products, today announced their intention to expand their strategic
alliance. The expansion, based on the partnership that was
established last year, builds upon the companies’ translational and
clinical cell therapy development platform originally designed to
more rapidly explore T cell-based immunotherapy therapy products in
Greater China. Specifically, the companies intend to add up to two
additional candidates from the 2seventy portfolio, one in solid
tumor indications using T-cell receptor (TCR) based technology and
a second in autoimmune disease using a CAR T cell approach.
“Since our partnership was established, our companies have built
a deeply collaborative and successful approach to progressing cell
therapy candidates,” said Steve Bernstein, chief medical officer,
2seventy bio. “At the time, our primary goal was to build a
collaboration with a focus on our potency-enhanced MAGE-A4 solid
tumor program that could demonstrate our collective capabilities to
rapidly test, learn and progress our innovative cell therapy
programs to the clinic. We’re excited to have done just that, with
this initial program running ahead of schedule and on track to
initiate an investigator-initiated study in China by the end of
this year. Given the progress with MAGE-A4, today’s announcement is
a natural evolution, doubling down on the success to date by
extending our collaboration into additional programs in solid
tumors and autoimmune disease.”
As announced in October 2022, the initial focus of the
collaboration was 2seventy bio’s potency enhanced MAGE-A4 TCR
program in solid tumors which is being developed as part of a
collaboration with Regeneron. Over the last 10 months, JW
Therapeutics has successfully progressed this candidate and is on
track to initiate an investigator-initiated study in China by the
end of 2023 and well ahead of the original timeline. In addition to
the pace of development, the significantly better cost structure of
preclinical and early clinic development performed through JW
Therapeutics’ internal and external development network provides
additional rationale for further collaboration. To this end, the
intent of the expanded collaboration is to add two new programs: an
additional solid tumor program and 2seventy’s first autoimmune
disease (AID) targeted CAR T cell program.
2seventy’s AID program is a natural extension of its’ internal
expertise in CAR T cell research and significant clinical
experience in both B-cell targeted and plasma cell-targeted CAR T
cells in oncology – the two antibody secreting cell types in the
body that play a role in the pathobiology of autoimmune disorders.
2seventy’s construct has been designed to achieve the breadth and
depth of target cell elimination necessary to potentially provide a
superior outcome for patients suffering from the plethora of
antibody-mediated autoimmune diseases.
“From the start of our collaboration with 2seventy bio last
year, we knew that there was the potential of working on other
assets in China so we are excited to announce the intended
expansion of our partnership,” said Dr. Mark J. Gilbert, Chief
Medical Officer, JW Therapeutics. “Our work together has proven
that combining our companies’ strength and capabilities carries
significant advantages including world-class translational
research, process development and clinical development. We look
forward to building upon our success, incorporating 2seventy’s
advanced technology and collaborating with their highly-experienced
team to accelerate the development of potential new medicines with
breakthrough therapeutic value to serve more patients in China and
possibly worldwide. This is testament to the highly versatile
application and effectiveness of our end-to-end platform that
successfully expedite our as much as third party R&D
processes.”
About JW Therapeutics
JW Therapeutics (HKEX: 2126) is an independent and innovative
biotechnology company focusing on developing, manufacturing and
commercializing cell immunotherapy products. Since our founding in
2016, JW Therapeutics has built an integrated platform for product
development in cell immunotherapy, as well as a product pipeline
covering both hematologic malignancies, solid tumors and autoimmune
diseases. JW Therapeutics is committed to bringing breakthrough and
quality cell immunotherapy products and the hope of a cure to
patients in China and beyond, and to leading the healthy and
standardized development of China’s cell immunotherapy industry.
For more information, please visit www.jwtherapeutics.com.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME.
Cancer rips time away, and our goal is to work at the maximum speed
of translating human thought into action – 270 miles per hour – to
give the people we serve more time. We are building the leading
immuno-oncology cell therapy company, focused on discovering and
developing new therapies that truly disrupt the cancer treatment
landscape.
With a deep understanding of the human body’s immune response to
tumor cells and how to translate cell therapies into practice,
we’re applying this knowledge to deliver next generation cellular
therapies that focus on a broad range of hematologic malignancies,
including the first FDA-approved CAR T cell therapy for multiple
myeloma, as well as solid tumors. Our research and development is
focused on delivering therapies that are designed with the goal to
“think” smarter and faster than the disease. Importantly, we remain
focused on accomplishing these goals by staying genuine and
authentic to our “why” and keeping our people and culture top of
mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and
LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
Cautionary Note Regarding Forward-Looking Statements of
2seventy bio
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to: statements about
our plans, strategies, timelines and expectations with respect to
the development, manufacture or sale of our product candidates,
including the results and expected timing of ongoing and planned
clinical trials for our product candidates in China and the speed
with which we can bring those candidates into clinical trials;
statements about the efficacy and perceived therapeutic benefits of
our product candidates and their potential indications; statements
about the strategic plans for 2seventy bio and potential corporate
development opportunities; statements regarding the company’s
intention to expand the strategic alliance with JW Therapeutics;
and statements about our ability to execute our strategic
priorities. Any forward-looking statements in this press release
are based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and important factors
that may cause actual events or results to differ materially from
those expressed or implied by any forward-looking statements
contained in this press release, including, without limitation, the
risk that our plans with respect to the preclinical and clinical
development and regulatory approval of our product candidates may
not be successfully achieved on the planned timeline, or at all.
For a discussion of other risks and uncertainties, and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in our annual report on Form
10-K for the year ended December 31, 2022, as supplemented and/or
modified by our most recent Quarterly Report on Form 10-Q and any
other filings that we have made or will make with the Securities
and Exchange Commission in the future. All information in this
press release is as of the date of the release, and 2seventy bio
undertakes no duty to update this information unless required by
law.
Forward-Looking Statements of JW Therapeutics
The forward-looking statements are based on the management's
expectations and beliefs and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described. Significant risks and uncertainties, include
those discussed below and more fully described in Hong Kong
Exchanges and Clearing Limited (HKEX) reports filed by the Company.
Unless otherwise noted, the Company is providing this information
as of the date it publicized, and expressly disclaims any duty to
update information contained in the issues and relevant
information, or provide any explanation. For detailed information,
please visit the company website:
www.jwtherapeutics.com/en/forward-looking-statements/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912702923/en/
2seventy bio
Investors: Elizabeth Pingpank Hickin, 860-463-0469
Elizabeth.pingpank@2seventybio.com
Media: Jenn Snyder, 617-448-0281
Jenn.snyder@2seventybio.com Morgan Adams Shields, 774-313-9852
morgan.adams@2seventybio.com
JW Therapeutics
Investors: IR_JW@jwtherapeutics.com
Media: Communications@jwtherapeutics.com
2seventy bio (NASDAQ:TSVT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
2seventy bio (NASDAQ:TSVT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024